To verify whether EMP1 promotes HSC activation to aggravate MASLD-IRI-induced liver injury through the TLN1/FAK signaling axis, we established EMP1-silenced animal models via tail vein injection of AAV6-shRNA, selected for its efficient targeting of HSCs [25, 42, 43]. Here, PTK2 is linked to metabolic dysfunction-associated steatotic liver disease.